Incorrect biopsy results cloud Nymox Pharma prostate cancer study

April 30, 2014 2:16 PM

18 0

(Reuters) - Nymox Pharmaceutical Corp said its experimental prostate cancer drug reduced the progression of cancer in patients, but it could not determine if the study succeeded in meeting pre-determined goals due to a high rate of incorrect biopsies.

In the mid-stage study, patients receiving a single injection of the drug, NX-1207, had less cancer progression in the treated area than in untreated patients.

Read more

To category page